Department of Public Health and Caring Sciences, Uppsala University, Box 564, SE-751 22, UPPSALA, Sweden.
Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
BMC Med Inform Decis Mak. 2018 Nov 20;18(1):106. doi: 10.1186/s12911-018-0662-2.
Common measures used to describe preventive treatment effects today are proportional, i.e. they compare the proportions of events in relative or absolute terms, however they are not easily interpreted from the patient's perspective and different magnitudes do not seem to clearly discriminate between levels of effect presented to people.
In this randomised cross-sectional survey experiment, performed in a Swedish population-based sample (n = 1041, response rate 58.6%), the respondents, aged between 40 and 75 years were given information on a hypothetical preventive cardiovascular treatment. Respondents were randomised into groups in which the treatment was described as having the effect of delaying a heart attack for different periods of time (Delay of Event, DoE): 1 month, 6 months or 18 months. Respondents were thereafter asked about their willingness to initiate such therapy, as well as questions about how they valued the proposed therapy.
Longer DoE:s were associated with comparatively greater willingness to initiate treatment. The proportions accepting treatment were 81, 71 and 46% when postponement was 18 months, 6 months and 1 month respectively. In adjusted binary logistic regression models the odds ratio for being willing to take therapy was 4.45 (95% CI 2.72-7.30) for a DoE of 6 months, and 6.08 (95% CI 3.61-10.23) for a DoE of 18 months compared with a DoE of 1 month. Greater belief in the necessity of medical treatment increased the odds of being willing to initiate therapy.
Lay people's willingness to initiate preventive therapy was sensitive to the magnitude of the effect presented as DoE. The results indicate that DoE is a comprehensible effect measure, of potential value in shared clinical decision-making.
目前用于描述预防治疗效果的常用指标是比例性的,即它们以相对或绝对的术语比较事件的比例,但从患者的角度来看,这些指标不容易解释,而且不同的幅度似乎不能清楚地区分呈现给人们的效果水平。
在这项在瑞典基于人群的样本中进行的随机横断面调查实验中(n=1041,响应率为 58.6%),年龄在 40 至 75 岁之间的受访者收到了关于一种假设的预防心血管治疗的信息。受访者被随机分为几组,其中治疗效果被描述为延迟心脏病发作的不同时间段(事件延迟,DoE):1 个月、6 个月或 18 个月。此后,受访者被问及他们是否愿意开始这种治疗,以及他们如何评估拟议的治疗。
较长的 DoE 与治疗意愿增加有关。当延迟时间为 18 个月、6 个月和 1 个月时,接受治疗的比例分别为 81%、71%和 46%。在调整后的二元逻辑回归模型中,与 1 个月 DoE 相比,6 个月 DoE 的治疗意愿比值比(OR)为 4.45(95%CI 2.72-7.30),18 个月 DoE 的 OR 为 6.08(95%CI 3.61-10.23)。对医疗必要性的更大信念增加了愿意开始治疗的可能性。
普通民众对预防治疗的意愿对呈现的效果大小(DoE)敏感。结果表明,DoE 是一种可理解的效果测量指标,在共同的临床决策中具有潜在价值。